Karah Parschauer is the Chief Legal Officer & Corporate Affairs and Executive Vice President at Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development and commercialization of novel products for rare and ultra-rare genetic diseases. In her role, Parschauer is responsible for overseeing the company's legal affairs, corporate governance, and strategic initiatives, ensuring that Ultragenyx remains at the forefront of the industry while adhering to regulatory requirements. Parschauer brings a wealth of experience to her position, having previously served as the Executive Vice President, General Counsel, and Secretary at Hyperion Therapeutics, Inc. During her tenure at Hyperion, she played a crucial role in the company's growth and success, culminating in its acquisition by Horizon Pharma plc in 2015. Her expertise in the life sciences sector, combined with her strategic vision, has been instrumental in guiding Ultragenyx through the complex landscape of drug development and commercialization. As a leader at Ultragenyx, Parschauer has been instrumental in fostering a culture of innovation and collaboration. She works closely with the executive team to identify and pursue opportunities that align with the company's mission to develop transformative therapies for patients with rare genetic diseases. Her dedication to advancing the company's goals, coupled with her extensive legal and business acumen, has solidified her position as a valuable asset to Ultragenyx and the broader biopharmaceutical community.